Immunization of Saimiri sciureus Monkeys with a Recombinant Hybrid Protein Derived from the Plasmodium falciparum Antigen Glutamate-Rich Protein and Merozoite Surface Protein 3 Can Induce Partial Protection with Freund and Montanide ISA720 Adjuvants
Open Access
- 1 February 2005
- journal article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 12 (2) , 242-248
- https://doi.org/10.1128/cdli.12.2.242-248.2005
Abstract
The immunogenicity and efficacy of a hybrid recombinant protein derived from the N-terminal end of the glutamate-rich protein (GLURP) and the C-terminal portion of the merozoite surface protein 3 (MSP3) of Plasmodium falciparum was evaluated in Saimiri sciureus monkeys. The GLURP/MSP3 hybrid protein, expressed in Lactococcus lactis , was administered in association with alum, Montanide ISA720, or complete or incomplete Freund adjuvant (CFA/IFA) in groups of five animals each. The three formulations were shown to be immunogenic, but the one with alum was shown to be weak compared to the other two, particularly CFA/IFA, which provided very high antibody titers (enzyme-linked immunosorbent assay titers of >3,000,000 and immunofluorescence antibody test titers of 6,400). After a challenge infection with P. falciparum FUP strain, all five monkeys from the GLURP/MSP3-alum group showed a rapid increase in parasitemia, reaching 10% and were treated early. The two monkeys with the highest antibody titers in group GLURP/MSP3-Montanide ISA720 had a delay in the course of parasitemia and were treated late due to a low hematocrit. In the GLURP/MSP3-CFA/IFA group, parasitemia remained below this threshold in four of the five animals and, after it reached a peak, parasitemia started to decrease and monkeys were treated late. When all animals were grouped according to the outcome, a statistically significant association between high antibody titers and partial protection was observed. The challenge infection boosted the antibody titers, and the importance of this event for vaccine efficacy in areas where this parasite is endemic is discussed. In conclusion, these data suggest that GLURP and MSP3 can induce protection against malaria infection if antibodies are induced at properly high titers.Keywords
This publication has 15 references indexed in Scilit:
- Immunization of Saimiri sciureus Monkeys with Plasmodium falciparum Merozoite Surface Protein‐3 and Glutamate‐Rich Protein Suggests that Protection is Related to Antibody LevelsScandinavian Journal of Immunology, 2004
- A Plasmodium falciparum GLURP–MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodiesVaccine, 2004
- Severe anemia affects both splenectomized and non-splenectomized Plasmodium falciparum-infected Aotus infulatus monkeys.Memórias do Instituto Oswaldo Cruz, 2003
- Aotus monkeys: their great value for anti-malaria vaccines and drug testingInternational Journal for Parasitology, 2002
- Malaria Vaccine: Candidate Antigens, Mechanisms, Constraints and ProspectsScandinavian Journal of Immunology, 2002
- Merozoite Surface Protein 3 and Protection against Malaria inAotus nancymaiMonkeysThe Journal of Infectious Diseases, 2002
- Selection of Glutamate-Rich Protein Long Synthetic Peptides for Vaccine Development: Antigenicity and Relationship with Clinical Protection and ImmunogenicityInfection and Immunity, 2001
- The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burdenThe American Journal of Tropical Medicine and Hygiene, 2001
- Immunogenicity and Efficacy inAotusMonkeys of Four RecombinantPlasmodium falciparumVaccines in Multiple Adjuvant Formulations Based on the 19-Kilodalton C Terminus of Merozoite Surface Protein 1Infection and Immunity, 2000
- Primary structure and localization of a conserved immunogenicPlasmodium falciparum glutamate rich protein (GLURP) expressed in both the preerythrocytic and erythrocytic stages of the vertebrate life cycleMolecular and Biochemical Parasitology, 1991